Juno Therapeutics, Inc. (NASDAQ:JUNO) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

Juno Therapeutics, Inc. Exhibit
EX-99.1 2 d531432dex991.htm EX-99.1 EX-99.1 Exhibit 99.1        CELGENE CORPORATION TO ACQUIRE JUNO THERAPEUTICS,…
To view the full exhibit click here

About Juno Therapeutics, Inc. (NASDAQ:JUNO)

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171) and JCAR020: MUC-16/IL-12. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.